Survival and Response Outcomes for Gastrointestinal Neuroendocrine Tumor (GEP-NETs) Patients Treated with Lutetium-177-DOTATATE in a Brazilian Reference Center: A Six-Year Follow-Up Experience.

Zenaide Silva de Souza Camila Bragança Xavier Luciana Beatriz Mendes GomesMaria Fernanda Barbosa de MedeirosMicelange Carvalho de SousaAllan Andresson Lima PereiraJosé Flávio Gomes MarinCarlos Alberto BuchpiguelFrederico Perego Costa

Published in: Cancers (2023)

PRRT provides long-term PFS in patients with G1/G2 GEP-NETs independent of clinical characteristics and primary site. G3 has worse survival, but selected patients may experience long OS after PRRT treatment.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
free survival
prognostic factors
pet ct
metabolic syndrome
patient reported outcomes